Jan Lindebjerg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jan Lindebjerg has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Anders Jakobsen
Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark
9 shared publications - Søren Rafael Rafaelsen
University of Southern Denmark
3 shared publications - Flemming Brandt Sørensen
Danish Colorectal Cancer Center South, Vejle Hospital, Vejle, Denmark
2 shared publications Gert Bruun-Petersen
2 shared publications- Ivan Brandslund
University of Southern Denmark, Vejle Hospital
2 shared publications John Ploen
Department of Oncology, Vejle Hospital, Vejle, Denmark
2 shared publications
Latest Publications
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e15620
Feasibility of molecular patient selection in rare cancers: Phase II study of gemcitabine, oxaliplatin and capecitabine in KRAS mutated biliary tract cancer.
E15620 Background: KRAS mutations occur in biliary tract cancer (BTC) at a low rate and little is known as to prognosis and response to chemotherapy for this subgroup. This is the first prospective study to report the outcome of combination chemotherapy in BTC patients with a prespecified molecular characteristic of KRAS mutation. The aim was to investigate the feasibility of combination chemotherapy in patients with KRAS mutated BTC. Methods: From 2009 to 2015 25 patients were included from two Scandinavian centers. Main inclusion criteria were non-resectable biliary tract cancer, performance status 0-2 and tumor KRAS mutation. Chemotherapy was given in a two-week cycle with gemcitabine 1000 mg/m2 and oxaliplatin 85 mg/m2 day 1 followed by 7 days of capecitabine 1000 mg/m2 bid. Response evaluation was done every six treatments and the primary endpoint was the fraction of PFS at 6 months. ClinicalTrials.gov NCT00779454. Results: Sixteen females and 9 males were included and the median age was 69 years (range 50-80). Performance status was 0 (n = 7), 1 (n = 11) and 2 (n = 7). Seventeen patients had metastatic disease and 8 had locally advanced disease. Chemotherapy was given for a median of 5 full months (range 0-14). One grade 4 (febrile neutropenia) and 6 grade 3 toxicity (febrile neutropenia, hyperglycemia and urticaria) was observed, while the commonest grade 1-2 toxicities were neurotoxicity, nausea or vomiting. Among 17 patients evaluable for response, 1 complete and 2 partial responses were seen and the rest had stable disease as best response. 18 patients had progression documented with CT-scans, 6 died between planned evaluations and one patient is still alive without progression. Median PFS was 6.8 months (95% CI 3.1-11.0) and median overall survival was 11.2 months (95% CI 6.6-14.3). The fraction of PFS at 6 months was 52% (95% CI 31-69%). Conclusions: Combination chemotherapy was feasible and the results with a PFS and OS of 6.8 and 11.2 months, respectively, point to an effect in patients with KRAS mutation similar to that of unselected patient populations. Clinical trial information: NCT00779454.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e15620
Feasibility of molecular patient selection in rare cancers: Phase II study of gemcitabine, oxaliplatin and capecitabine in KRAS mutated biliary tract cancer.
E15620 Background: KRAS mutations occur in biliary tract cancer (BTC) at a low rate and little is known as to prognosis and response to chemotherapy for this subgroup. This is the first prospective study to report the outcome of combination chemotherapy in BTC patients with a prespecified molecular characteristic of KRAS mutation. The aim was to investigate the feasibility of combination chemotherapy in patients with KRAS mutated BTC. Methods: From 2009 to 2015 25 patients were included from two Scandinavian centers. Main inclusion criteria were non-resectable biliary tract cancer, performance status 0-2 and tumor KRAS mutation. Chemotherapy was given in a two-week cycle with gemcitabine 1000 mg/m2 and oxaliplatin 85 mg/m2 day 1 followed by 7 days of capecitabine 1000 mg/m2 bid. Response evaluation was done every six treatments and the primary endpoint was the fraction of PFS at 6 months. ClinicalTrials.gov NCT00779454. Results: Sixteen females and 9 males were included and the median age was 69 years (range 50-80). Performance status was 0 (n = 7), 1 (n = 11) and 2 (n = 7). Seventeen patients had metastatic disease and 8 had locally advanced disease. Chemotherapy was given for a median of 5 full months (range 0-14). One grade 4 (febrile neutropenia) and 6 grade 3 toxicity (febrile neutropenia, hyperglycemia and urticaria) was observed, while the commonest grade 1-2 toxicities were neurotoxicity, nausea or vomiting. Among 17 patients evaluable for response, 1 complete and 2 partial responses were seen and the rest had stable disease as best response. 18 patients had progression documented with CT-scans, 6 died between planned evaluations and one patient is still alive without progression. Median PFS was 6.8 months (95% CI 3.1-11.0) and median overall survival was 11.2 months (95% CI 6.6-14.3). The fraction of PFS at 6 months was 52% (95% CI 31-69%). Conclusions: Combination chemotherapy was feasible and the results with a PFS and OS of 6.8 and 11.2 months, respectively, point to an effect in patients with KRAS mutation similar to that of unselected patient populations. Clinical trial information: NCT00779454.
- 13 February 2013
- Published by Elsevier in European Journal of Radiology
- Vol. 82 (6) , 913-917
Ultrasound elastography in patients with rectal cancer treated with chemoradiation
- 13 February 2013
- Published by Elsevier in European Journal of Radiology
- Vol. 82 (6) , 913-917
Ultrasound elastography in patients with rectal cancer treated with chemoradiation
- 25 June 2012
- Vol. 174 (26) , 1826-7
[MRI of rectal stromal tumour].
A 39-year-old man was referred to hospital with a rectal tumour and underwent gastrointestinal endoscopy and diagnostic imaging. The tumour had immunohistochemical characteristics for gastrointestinal stromal tumour (GIST). The differential diagnosis of GIST to adenocarcinoma is important to be aware of for the rectal multidisciplinary team. On suspicion of GIST, patients should be referred to a sarcoma centre. The diagnosis of rectal GIST can be suggested on MRI by the presence of a well-defined heterogeneously large mass with a necrotic center associated with a prominent extra-luminal component and hyperechoic appearance on ultrasound.
- 25 June 2012
- Vol. 174 (26) , 1826-7
[MRI of rectal stromal tumour].
A 39-year-old man was referred to hospital with a rectal tumour and underwent gastrointestinal endoscopy and diagnostic imaging. The tumour had immunohistochemical characteristics for gastrointestinal stromal tumour (GIST). The differential diagnosis of GIST to adenocarcinoma is important to be aware of for the rectal multidisciplinary team. On suspicion of GIST, patients should be referred to a sarcoma centre. The diagnosis of rectal GIST can be suggested on MRI by the presence of a well-defined heterogeneously large mass with a necrotic center associated with a prominent extra-luminal component and hyperechoic appearance on ultrasound.
- Open Access
- 8 March 2012
- Published by Springer Nature in BMC Cancer
- Vol. 12 (1) , 83
The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer
MicroRNA-126 is the only microRNA (miRNA) known to be endothelial cell-specific influencing angiogenesis in several ways. The aim of the present study was to analyse the possible predictive value of miRNA-126 in relation to first line capecitabine and oxaliplatin (XELOX) in patients with metastatic colorectal cancer (mCRC).
- 8 March 2012
- Published by Springer Nature in BMC Cancer
- Vol. 12 (1) , 83
Open AccessThe predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer
MicroRNA-126 is the only microRNA (miRNA) known to be endothelial cell-specific influencing angiogenesis in several ways. The aim of the present study was to analyse the possible predictive value of miRNA-126 in relation to first line capecitabine and oxaliplatin (XELOX) in patients with metastatic colorectal cancer (mCRC).
- Open Access
- 19 July 2011
- Published by Wiley in Histopathology
- Vol. 59 (1) , 18-21
Factors influencing reproducibility of tumour regression grading after high-dose chemoradiation of locally advanced rectal cancer
International audienceHigh dose chemoradiation is now considered standard treatment of locally advanced rectal cancer. To provide feedback on the effect of this treatment, several regression grading systems have been proposed. For a grading system to be useful it has to be reproducible. The aim of this study was to test the reproducibility of a five point grading system, originally proposed by Mandard, and to describe the sources of disagreement. Tumor regression was assessed independently by two observers on 100 consecutive chemo radiated rectal cancer specimens. The grading system was very reproducible with weighted and unweighted kappa values of 0,89 and 0,82 respectively. The most frequent source of disagreement was assessment of the relative amount of fibrosis. Displacement of epithelium was a minor source
- 19 July 2011
- Published by Wiley in Histopathology
- Vol. 59 (1) , 18-21
Open AccessFactors influencing reproducibility of tumour regression grading after high-dose chemoradiation of locally advanced rectal cancer
International audienceHigh dose chemoradiation is now considered standard treatment of locally advanced rectal cancer. To provide feedback on the effect of this treatment, several regression grading systems have been proposed. For a grading system to be useful it has to be reproducible. The aim of this study was to test the reproducibility of a five point grading system, originally proposed by Mandard, and to describe the sources of disagreement. Tumor regression was assessed independently by two observers on 100 consecutive chemo radiated rectal cancer specimens. The grading system was very reproducible with weighted and unweighted kappa values of 0,89 and 0,82 respectively. The most frequent source of disagreement was assessment of the relative amount of fibrosis. Displacement of epithelium was a minor source
- 1 May 2011
- Vol. 31 (5) , 1559-65
Pretreatment HIF-1α and GLUT-1 expressions do not correlate with outcome after preoperative chemoradiotherapy in rectal cancer.
The aim of the present study was to investigate hypoxia-inducible factor 1α (HIF-1α) and glucose transporter-1 (GLUT-1) expressions as predictors of response and survival after chemoradiotherapy in pretreatment biopsy specimens from patients with rectal cancer. The immunohistological expressions of HIF-1α and GLUT-1 were investigated in pretreatment biopsies from 86 patients with rectal cancer receiving long course preoperative chemoradiotherapy. The immunohistological stainings were scored semi-quantitatively (percentage of stained cells and staining intensity), and an immunoreactive score was calculated. The response to the chemoradiotherapy was assessed by the Mandard Tumour Regression Grade system (TRG). No association was found between HIF-1α or GLUT-1 and clinicopathological variables. HIF-1α and GLUT-1 expression had no predictive impact regarding response to chemoradiotherapy measured by TRG and was not associated with overall survival. The present study did not suggest any predictive or prognostic value of pretreatment HIF-1α or GLUT-1 expression in patients with rectal cancer treated with preoperative chemoradiotherapy.
- 1 May 2011
- Vol. 31 (5) , 1559-65
Pretreatment HIF-1α and GLUT-1 expressions do not correlate with outcome after preoperative chemoradiotherapy in rectal cancer.
The aim of the present study was to investigate hypoxia-inducible factor 1α (HIF-1α) and glucose transporter-1 (GLUT-1) expressions as predictors of response and survival after chemoradiotherapy in pretreatment biopsy specimens from patients with rectal cancer. The immunohistological expressions of HIF-1α and GLUT-1 were investigated in pretreatment biopsies from 86 patients with rectal cancer receiving long course preoperative chemoradiotherapy. The immunohistological stainings were scored semi-quantitatively (percentage of stained cells and staining intensity), and an immunoreactive score was calculated. The response to the chemoradiotherapy was assessed by the Mandard Tumour Regression Grade system (TRG). No association was found between HIF-1α or GLUT-1 and clinicopathological variables. HIF-1α and GLUT-1 expression had no predictive impact regarding response to chemoradiotherapy measured by TRG and was not associated with overall survival. The present study did not suggest any predictive or prognostic value of pretreatment HIF-1α or GLUT-1 expression in patients with rectal cancer treated with preoperative chemoradiotherapy.
- Open Access
- 25 March 2011
- Published by Springer Nature in BMC Cancer
- Vol. 11 (1) , 107
EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer
As supplement to KRAS mutational analysis, BRAF and PIK3CA mutations as well as expression of PTEN may account for additional non-responders to anti-EGFR-MoAbs treatment. The aim of the present study was to investigate the utility as biomarkers of these mutations in a uniform cohort of patients with metastatic colorectal cancer treated with third-line cetuximab/irinotecan.
- 25 March 2011
- Published by Springer Nature in BMC Cancer
- Vol. 11 (1) , 107
Open AccessEGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer
As supplement to KRAS mutational analysis, BRAF and PIK3CA mutations as well as expression of PTEN may account for additional non-responders to anti-EGFR-MoAbs treatment. The aim of the present study was to investigate the utility as biomarkers of these mutations in a uniform cohort of patients with metastatic colorectal cancer treated with third-line cetuximab/irinotecan.
- 1 February 2011
- Published by Elsevier in Cancer Genetics
- Vol. 204 (2) , 84-95
Identification of chromosome aberrations in sporadic microsatellite stable and unstable colorectal cancers using array comparative genomic hybridization
- 1 February 2011
- Published by Elsevier in Cancer Genetics
- Vol. 204 (2) , 84-95
Identification of chromosome aberrations in sporadic microsatellite stable and unstable colorectal cancers using array comparative genomic hybridization
- Open Access
The Prognostic Value of Haplotypes in the Vascular Endothelial Growth Factor A Gene in Colorectal Cancer
New prognostic markers in patients with colorectal cancer (CRC) are a prerequisite for individualized treatment. Prognostic importance of single nucleotide polymorphisms (SNPs) in the vascular endothelial growth factor A (VEGF-A) gene has been proposed. The objective of the present study was to investigate the prognostic importance of haplotypes in the VEGF-A gene in patients with CRC. The study included 486 patients surgically resected for stage II and III CRC, divided into two independent cohorts. Three SNPs in the VEGF-A gene were analyzed by polymerase chain reaction. Haplotypes were estimated using the PHASE program. The prognostic influence was evaluated using Kaplan-Meir plots and log rank tests. Cox regression method was used to analyze the independent prognostic importance of different markers. All three SNPs were significantly related to survival. A haplotype combination, responsible for this effect, was present in approximately 30% of the patients and demonstrated a significant relationship with poor survival, and it remained an independent prognostic marker after multivariate analysis, hazard ratio 2.46 (95% confidence interval 1.49–4.06), p < 0.001. Validation was provided by consistent findings in a second and independent cohort. Haplotype combinations call for further investigation.
Open AccessThe Prognostic Value of Haplotypes in the Vascular Endothelial Growth Factor A Gene in Colorectal Cancer
New prognostic markers in patients with colorectal cancer (CRC) are a prerequisite for individualized treatment. Prognostic importance of single nucleotide polymorphisms (SNPs) in the vascular endothelial growth factor A (VEGF-A) gene has been proposed. The objective of the present study was to investigate the prognostic importance of haplotypes in the VEGF-A gene in patients with CRC. The study included 486 patients surgically resected for stage II and III CRC, divided into two independent cohorts. Three SNPs in the VEGF-A gene were analyzed by polymerase chain reaction. Haplotypes were estimated using the PHASE program. The prognostic influence was evaluated using Kaplan-Meir plots and log rank tests. Cox regression method was used to analyze the independent prognostic importance of different markers. All three SNPs were significantly related to survival. A haplotype combination, responsible for this effect, was present in approximately 30% of the patients and demonstrated a significant relationship with poor survival, and it remained an independent prognostic marker after multivariate analysis, hazard ratio 2.46 (95% confidence interval 1.49–4.06), p < 0.001. Validation was provided by consistent findings in a second and independent cohort. Haplotype combinations call for further investigation.
- 1 November 2006
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 29 (5) , 1159-1165
Epidermal growth factor receptor analyses in colorectal cancer: A comparison of methods
EGFR immunohistochemistry (IHC) status is not a reliable predictive marker for response to EGFR-targeted therapies. The present study compares the EGFR status at DNA, RNA and protein level. Blood samples, corresponding normal colon and colorectal cancer tissue were collected from 199 colorectal cancer (CRC) patients. EGFR status was evaluated by FISH analysis, real-time RT-PCR, ELISA and IHC. A polymorphism in the EGFR promoter was evaluated by PCR analysis. The EGFR levels by different methods were mutually compared. Seventy-eight percent of primary tumours and corresponding lymph nodes had equivalent EGFR status (28/34). There was a tendency to higher median protein level (by ELISA) in IHC positive patients compared to IHC negative patients (p=0.086). The median EGFR gene expression level was significantly lower in tumours than in the normal colon with no difference according to IHC status. No tumours had increased gene copy number by FISH. EGFR Sp1-216 polymorphism analysis showed a tendency for different EGFR tumour protein levels and gene expression levels according to the different genotypes. The results show a poor correlation between EGFR status at DNA, RNA and protein level. The predictive value of a combination of methods needs further evaluation in the clinical setting.
- 1 November 2006
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 29 (5) , 1159-1165
Epidermal growth factor receptor analyses in colorectal cancer: A comparison of methods
EGFR immunohistochemistry (IHC) status is not a reliable predictive marker for response to EGFR-targeted therapies. The present study compares the EGFR status at DNA, RNA and protein level. Blood samples, corresponding normal colon and colorectal cancer tissue were collected from 199 colorectal cancer (CRC) patients. EGFR status was evaluated by FISH analysis, real-time RT-PCR, ELISA and IHC. A polymorphism in the EGFR promoter was evaluated by PCR analysis. The EGFR levels by different methods were mutually compared. Seventy-eight percent of primary tumours and corresponding lymph nodes had equivalent EGFR status (28/34). There was a tendency to higher median protein level (by ELISA) in IHC positive patients compared to IHC negative patients (p=0.086). The median EGFR gene expression level was significantly lower in tumours than in the normal colon with no difference according to IHC status. No tumours had increased gene copy number by FISH. EGFR Sp1-216 polymorphism analysis showed a tendency for different EGFR tumour protein levels and gene expression levels according to the different genotypes. The results show a poor correlation between EGFR status at DNA, RNA and protein level. The predictive value of a combination of methods needs further evaluation in the clinical setting.